| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.4 |
| Net income | -22.3 | -13.8 |
| EPS (diluted, $ a share) | $-0.76 | $-3.44 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ATTO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Attovia Therapeutics, Inc.: key numbers
- Share price
- $14.86Close, Nov 17
- Market cap
- $678M
- Shares outstanding
- 45.65MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Attovia Therapeutics, Inc.
All →Attovia Therapeutics Clinical Trial Data
Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.
“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”
Tao Fu, Founder and Chief Executive Officer of Attovia